Pakola Steve's Form 4 filing
REGENXBIO Inc. (RGNX) · filed Jan 4, 2022
- Accession no.
- 0001562180-22-000159
- Filed
- Jan 4, 2022
- Trade date
- Jan 1-3, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $53.9K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pakola SteveCIK 0001700659 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 1, 2022 | Common Stock | FTax withholdingDisposed | −1,152 | $32.70 | −$37,670.4 | 9,848 | Direct | |
| Jan 3, 2022 | Common Stock | SSaleDisposed | −1,598 | $33.75F2 | −$53,932.5 | 8,250 | Direct | |
| Jan 3, 2022 | Common Stock | AGrant or awardAcquired | +8,900 | $0.00 | $0 | 17,150 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2022 | Common Stock | AGrant or awardAcquired | +42,500 | $0.00 | $0 | 42,500 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $33.72 to $33.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.